Abstract: Predicting druggability and prioritising certain disease modifying targets is critical in drug discovery. Expanding the spectrum of disease-relevant targets to pharmacological manipulation is vital to reducing morbidity and mortality. We test a druggability rule, based on 10 molecular parameters (scores counting violations, denoted by score10), which uses cutpoints for each molecular parameter based on mixture clustering discriminant analysis (MC/DA) (Hudson et al., 2014) . A total of 1279 small molecules from the DrugBank chem-informatics database (Knox et al., 2011) , combining detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with drug disease target information, were analysed and these were shown to be aligned with 173 targets. The score10 function comprised 4 traditional parameters of the rule of five (Ro5) (Lipinski, 2016) , plus 5 extra parameters (polar surface area PSA, number of rotatable bonds, rings and halogens, N and O atoms) with an extra candidate of lipophicility, log D (the distribution coefficient) recently suggested by Bhal et al., 2007 as a possible preferable predictor for permeation (Zafar, Hudson et al., 2016 , 2013 ) to Lipinski's traditional partition coefficient, Log P, a predictor for permeation.
INTRODUCTION
High throughput docking of small molecule ligands (candidate drugs) into high resolution protein structures is now standard in computational approaches to drug discovery (Ursu et al., 2017 (Ursu et al., , 2011 . Further details are in Hudson et al. (2016) , who investigated Self Organising Map (SOM) artificial neural network procedures as a computational tool for the evaluation of docking experiments of calpain ligands (small drug molecules) for the treatment of cataracts. Predicting druggability and prioritising certain disease modifying targets for drug development is of high practical relevance in pharmaceutical research (Rask-Anderson et al., 2011 , Lavecchia et al., 2015 . Druggability predictions are important to avoid intractable targets and to focus drug discovery research on sites with preferable prospects and mortality (Lazo & Sharlow, 2016) . Recently many targets have been classified as "undruggable" due to their lack of oral bioavailability. Generally, such targets have binding sites which are large, highly lipophilic, flexible, highly polar and featureless. This has in part created a momentum in small molecule drug discovery to move outside the Ro5 space, to the so-called beyond Ro5 (bRo5) space, noting that the Ro5 delineated cutpoints for Lipinski's traditional parameters (multiples of 5) by which if 1 violation occurred among the 4 parameters (highlighted in Table 2 ) the molecule was assumed Ro5 non-compliant. Recent drug studies suggest that cell permeable and orally bioavailable drugs have been discovered far into bRo5 space (Mattson et al., 2016) , which affords significantly more possibilities for orally bioavailable and cell permeable compounds . Too strict an implementation of the Ro5 may well have hampered the pharmaceutical industry in regard to finding novel and more difficult drugs as well as more conventional drug targets as the cutpoints of the first 3 of Lipinski parameters rules were rather lower (Table 2) . In this paper we tested a druggability rule based on 10 molecular parameters (scores counting violations, denoted score10) which uses cutpoints for each parameter based on mixture clustering discriminant analysis (MC/DA) (Hudson et al., 2014) . The score10 function comprised the 4 traditional parameters of rule of five (Ro5) highlighted in Table 2 , plus 5 extra parameters (PSA, number of rotatable bonds, rings, halogens, N and O atoms) with an extra candidate of permeability, log D (the distribution coefficient), suggested recently (Bhal et al., 2007) as a preferable predictor to Lipinski's partition coefficient, Log P.
DATA AND METHODS

Data and Druggability Scoring Rules
We analysed 1279 small molecules from the DrugBank database (Knox et al. 2011 ), a unique bioinformatics and chem-informatics resource combining detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with drug target (i.e. sequence, structure, pathway) information on 6,711 drug entries, and 1441 FDAapproved small molecule drugs (one candidate molecule example is shown in Table 1 ). Of the 1279 candidates there are 105 Ro5 violators, 681 and 598 with oral and non-oral delivery modes, respectively. Recently, Hudson et al. (2014) developed druggability rules (scores counting violations) which use a new cutpoint for each molecular parameter based on a mixture clustering (mclust) (Fraley et al., 2012 ) discriminant analysis (MC/DA) approach. Table 2 shows that the cut-off values of the Ro5 (Lipinski, 2016) , of Veber et al. (2002) and of Hudson et al. (2014) are not in agreement, particularly for MW, PSA and log P. However, Hudson et al.'s cutpoints are much in agreement with recent cutpoints of Ursu et al. (2017) , in particular for MW, log P and PSA (refer to columns 4-6 of Table 2 ). Note the cutpoint for Log D of 3.5 (Hudson et al., 2014) is smaller than 5.5 suggested earlier by Bhal et al. (2007) . Work by Zafar et al, (2013 Zafar et al, ( , 2016 also found the pH dependent version of permeability, log D at intestinal pH (log D ~ 3.5), superior to the classic parameter log P. 
Statistical Methods
Multivariate skew normal (SN) (Lee and Mc Lachlan 2014) and Gaussian (MN) mixture clustering were used to identify molecule groups based on the 10 predictors and to differentiate so-called good versus poor druggable candidates as in Hudson et al., (2014) . Logistic regression was performed to determine the best cutpoint, C, for the total number of violations, score10 (< C versus greater or equal to C, for C = 3, 4 or 5).
These thresholds for C were suggested by preliminary trends in clustering of Hudson et al., (2014) . The logit predictor models analysed here contain the molecule's Ro5 status (if Ro5 compliant, then druggable by Lipinski's rule), oral status, and poor vs good druggability based on the MN or SN clustering. Support vector machine (SVM) and Recursive partitioning (RP) based on the above 10 molecular descriptors was then used to classify compounds according to the partition -high or low Score10 values as defined by the optimal cutpoint. The data set was divided into a 959-molecule training set and a 320-molecule test set. RP was used to find simple hierarchical rules to classify the high score10 violators from the low (< C).
RESULTS
Logit analysis
Multivariate skew normal (SN) (Lee & Mc Lachlan 2014) and Gaussian (MN) mixture clustering identified 5 molecular groups based on the 10 predictors, or 7 clusters when based on 9 predictors, when the number of halogen atoms (h) was omitted (MN10-h, SN10-h models). The MN10 groups were highly differentiable with 3 of the 5 obtained clusters classified as poor druggable candidates (in total these 3 clusters contain 350 molecules). For either partition of the score10 function, with and without the number of halogen atoms included as a predictor of the clusters, logit models containing the MN10 cluster predictor were superior to the skew normal SN10 based models. The best MN10 model showed that molecules with 5 or more violations (AIC = 1403.79) tended to be non-oral candidates (p < 0.00001), MN10 poor (p < 0.00001) and be Ro5 violators (p < 0.00001) ( Table 3) . This optimal MN10 model gave a significant oral by cluster interaction (p < 0.02), in that for Ro5 compliant molecules, the predicted probability of scoring high (≥5) for the MN10 good molecules was 0.328 and 0.477, for oral and non-oral molecules, respectively. The probability of scoring ≥ 5 for the MN10 poor cluster was 0.750 and 0.757 for oral and non-oral Ro5 compliant molecules. For the Ro5 violators the predicted probability of scoring high (≥5) was 0.999 for both the poor and good MN10 classes, irrespective of their oral status. For the MN10 model, in terms of odds, the odds of a ligand scoring ≥ 5 increased by 0.527 for a ligand classified as non-oral and in the MN10 good cluster (with Ro5 status fixed). The odds of a molecule being a high scorer ≥5 increased by 3.014 if the molecule is classed as MN10 poor and oral (with Ro5 status fixed). The odds of a molecule being in the high score10 group increased by 3.13 if it is non oral and in the poor MN10 cluster (with Ro5 status fixed). The odds of a molecule being a high score violator increases by 94.54 if it is Ro5 noncompliant (with oral status and MN10 clustering fixed). Note the SN10 based logit models (where 433 molecules were classified as poor, based on k=7 SN10 clusters) did not demonstrate a significant oral by cluster interaction (not reported here). PRoC analyses (Robin et al., 2011) confirmed that a cutpoint of 5 for score10 is better than a cut-off of 4 to partition chemo-space (not reported here due to space restrictions), this optimal C of 5, was true for both the MN10 and SN10 based models, in agreement with the logit analysis. 
Disease target results
In this study, 173 targets for 1279 small molecules were retrieved from the data and the median score10 value obtained for the molecules in a given target group, where drug targets were associated with at least one FDA approved small drug. For example, if several molecules (say 40) are associated with one target, then the median values of score10 and of each of the 10 molecular descriptors that are used to evaluate score10 for 40 drugs were evaluated for that particular target. Of the 173 targets studied, 99 targets were predominantly oral and 74 non-oral in terms of modes of delivery. In this paper we report the top 12 targets which contain 25 or more molecules. Table 4 gives the disease target name for the top 12 targets, their associated number of molecules, median score10 value, overall oral status, along with the number of oral molecular candidates in the given target. For the twelve most representative targets to which 579 small molecules belong, Figure 1 shows the median values of 4 molecular descriptors, namely, molecular weight (MW) and log P of Lipinski (2016) , Polar Surface Area (PSA) of Veber et al (2002) ; and log D of Bhal et al., (2007) , latter used to compare with classical log P candidate for permeability. The targets with a median score10 of 5 or more (C= 5), were Anti-Bacterial, Antineoplastic, Antihypertensive and Anti-allergic, within which most of the drugs have a non-oral delivery mode (Table 4 ). Figure 1 displays the medians of Log P, MW, PSA and Log D across the top 12 disease targets. Figure1. Pattern of Log P, MW, PSA and Log D across the top twelve targets.
The pattern of molecular profiles of these 12 targets is shown in Figure 1 . For example, the Anti-Bacterial target drugs (with a median score10 of 6) were large in size (median MW = 453.66 daltons) compared to other targets and particularly compared to the Dietary target (median MW = 166.16 daltons). The median values of 3 descriptors representing hydrogen bond donors and acceptors (HBd, HBa)) or electrostatic features, HBa, HBd and PSA, were also high for the Anti-Bacterial target (10, 3.5 and 180.82, respectively) (Table 4-5). In addition, the median values for the Antihypertensive (non-oral) target drugs were high for HBa (6) and PSA (110.4) as was the median score10 of 5 (Fig. 1 ). The Dietary target had the lowest median score10, median MW and negative medians for both log P = -2.45 and log D = -2.81 (Table 5) . Notably most drugs of these 3 targets (Anti-bacterial, Dietary, Antihypertensive) were non-oral but Ro5 compliant.
The Antimetabolites target had a low median score10 of 1, low median MW = 244.2, but high PSA = 111.18, and negative median values for log P = -1.0 and log D = -0.75. Negative median values indicate higher hydrophobicity for both the Dietary and Antimetabolites target drugs. Noteworthy, the median values of log P = 3.4 and log D = 3.58 for the Anti-allergic target drugs (non-oral, with a median score10 of 5) were higher than the other 11 target groups (Figure 1 ) evidencing that the anti-allergic drugs may prefer not to transport hydrophobic molecules; followed then by the Antihypertensive and Anti-inflammatory targets (non-oral) with respective median score10 of 5 and 4. Interestingly, median Log D for Antibacterial target drugs was negative -1.49 versus 0.20 for log P, indicating that log D and log P contain different information as suggested by Bhal et al., (2007) .
SVM and RP results
The SVM classifier for our score10 partition (with cutpoint 5) yielded a Matthews coefficient C= 0. Figure 2 with Table  2 ). The numbers and labels inside the rounded rectangles delineate the number at each recursive partitioning step that satisfy or not the node cutpoint , the ligands are then split into the good and poor partitions based on score 10 at the next recursive step. For example in the validation set of 320 ligands with the partition good C < 5, vs poor C > 5) 197 satisfy MW < 342 and are classed good (RHS Fig. 2) , and 123 plased in the poor partition, for which MW exceeds 342. Of the 197 good ligands, 183 satisfy MW < 306 -at the next step, these are classed as good, of the 27 remaining molecules (183-156= 27) molecules (those with log D < 4.3 are in good score10 partition, 13 with log D > 4.3 are classed as poor. Note 156+27 = 183 and 1 + 13 = 14. The RP classification tree also supports the value of using log D < 3.5 (< 4.3) (left hand arms of Fig. 2 
DISCUSSION AND CONCLUSIONS
Our work illustrates that a simple scoring function of counts of violations can partition chemospace and help identify both good and poor druggable molecules, and associated targets. Moreover, ligands with 5 or more violations, based on adding subcomponents of score10, were shown to be associated with specific disease targets. The Anti-Bacterial target drugs (median score10 = 6) were found to have high values for all 10 molecular parameters, consistent with the results of Giordanetto et al., (2014) , who reported that compounds that fall into the bRo5 space (higher MW and PSA) include the Anti-bacterial target. In contrast Dietary target drugs had low values for the 10 descriptors, lowest median score10 of 1, lowest median MW and also negative medians for both log P = -2.45 and log D = -2.81. Further work that aims to evaluate which of the Log D and Log P best reflects permeability will test different score functions, based on 9 parameters, which respectively omit Log P (score9D) and log D (score9P), and find associated best score cutpoints (Hudson et al., in prep) . Recently log P's association with MW and PSA was shown to change magnitude/sign according to the molecule's Lipinski's Ro5, not so for log D (Zafar et al., 2016; 2013) . Consequently future work will test for Log P and Log D's association with the remaining ligand parameters, according to the new strata based on our score10 partition (< 5 vs ≥ 5) in this paper and in regard to new partitions based on 9 parameters. Ongoing work using mixture clustering of the target-specific medians of the 10 molecular parameters aims to help identify so-called poor and good targets. How these targets correlate with new partitions based on 9 molecular parameters is a future research topic (Hudson, Shafi et al., in prep) .
